Insulin– tag –
-
Dexcom Expands Beyond Diabetes Sensors to Comprehensive Health Platform with G8 Launch, Stelo Introduction, and FDA TEMPO Program Inclusion
Libre Life USA Overview Dexcom is transforming from a diabetes sensor manufacturer into a broader connected health platform, marked by the announcement of its next-gen G8 CGM, a 15-day wear extension for G7 internationally, and the launc... -
Vertex Pharmaceuticals Secures FDA IND Approval for iPSC-Derived Type 1 Diabetes Therapies, Boosts 2026 Revenue Forecast
Vertex Pharmaceuticals USA Overview Vertex Pharmaceuticals announced robust Q2 2026 financial results and significantly raised its full-year revenue guidance, propelled by key pipeline advancements. The company secured FDA Investigationa... -
FDA Clears Dexcom’s Stelo Glucose Biosensor System as First OTC Continuous Glucose Monitor for Non-Insulin-Using Children Ages 2+
Weence.com USA Overview On June 12, 2026, the FDA approved Dexcom's Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM) for children aged 2 and older who do not use insulin. This system, wh... -
DexCom Reports Strong Q2 2026 Results with 13% Revenue Growth, 50% Operating Income Surge
Stock Titan USA Overview DexCom announced robust Q2 2026 financial results, with revenue up 13% year-over-year, driven by increased disposable sensor volumes and an expanding customer base. The company also reported a significant 50% ris... -
Dexcom G7 Achieves Industry-Leading Accuracy with MARD 8.2-8.5% in Adults, Clinical Data Confirms
diabetesknow.com USA Overview Newly compiled clinical data for 2026 ranks the Dexcom G7 as the most accurate continuous glucose monitor (CGM), reporting a mean absolute relative difference (MARD) of approximately 8.2–8.5% in adults. This... -
FDA Clears Dexcom’s Stelo OTC Continuous Glucose Monitor for Non-Insulin Users Aged Two and Up
Prime Therapeutics - Portal USA Overview The FDA has granted over-the-counter (OTC) marketing authorization for Dexcom's Stelo Glucose Biosensor System, expanding its use to non-insulin users aged two and older. This marks the first OTC ... -
Century Therapeutics Pivots iPSC Platform to Type 1 Diabetes Beta Cell Therapy, Targeting 2025 IND with Off-the-Shelf Approach
Century Therapeutics USA Overview Century Therapeutics has announced a strategic realignment of its induced pluripotent stem cell (iPSC) platform, now exclusively dedicated to developing beta islet cell therapy for Type 1 Diabetes. The c... -
Medtronic Simplifies Diabetes Management with Integrated MiniMed 780G and Simplera Sync™ Sensor
Southeast Diabetes Inc. USA Overview Medtronic has introduced a state-of-the-art diabetes management solution, pairing its MiniMed 780G insulin pump system with the Simplera Sync™ sensor. Simplera Sync™ is an all-in-one, disposable conti... -
RT-CGM Reduces Inpatient and Emergency Department Encounters, Cutting Healthcare Costs for Non-Insulin-Treated Type 2 Diabetes Patients
PubMed USA Overview A retrospective study using US administrative claims data reveals that real-time continuous glucose monitoring (RT-CGM) significantly reduces healthcare resource utilization and associated medical costs among non-insu... -
Dexcom’s Stelo Achieves OTC Approval, Leading CGM Market for Non-Insulin Type 2 Diabetes Patients
CNET USA Overview Dexcom's Stelo has received FDA over-the-counter (OTC) approval, establishing it as a market leader in continuous glucose monitoring (CGM) for non-insulin users with Type 2 diabetes. The device provides real-time glucos...
